← Back
Data updated: Sep 20, 2026
MILLICENT MFG PR
Pharma Pharmaceuticals
MILLICENT MFG PR is a pharmaceutical company with 2 FDA-approved products.
2003
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules
MILLICENT MFG PR's Key Drugs
MILLICENT MFG PR's core commercial portfolio centers on FEMLYV — its most strategically important drugs approved in the last 15 years.
MILLICENT MFG PR's Recent FDA Approvals
New NDA/BLA approvals for MILLICENT MFG PR over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
MILLICENT MFG PR's Therapeutic Areas
Disease areas where MILLICENT MFG PR has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
MILLICENT MFG PR Pipeline Snapshot
Active clinical trials for MILLICENT MFG PR across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • FEMLYV leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2003-03-20
- Latest
- 2025-07-29
- Applications
- 2